Skip to content
Menu

JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $100

Benzinga Newsdesk 11 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $103 to $100.

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $103 to $100.

Read at benzinga.com

← All stock news